NCCN Guidelines® Insights - Prostate Cancer Early Detection, Version 1.2023
These NCCN Guidelines Insights provide a summary of recent updates to the NCCN Guidelines with regard to the testing protocol, use of multiparametric MRI, and management of negative biopsy results to optimize the detection of clinically significant prostate cancer and minimize the detection of indolent disease.
Category
- Prostate Cancer
Format
- Monograph/Journal Supplement
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
NCCN Guidelines® Insights - Non–Small Cell Lung Cancer, Version 2.2023
The NCCN Guidelines for Non–Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC.
Category
- Lung Cancers
Format
- Monograph/Journal Supplement
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Archived Monthly Oncology Tumor Boards: Esophageal and Esophagogastric Junction Cancers: Postoperative Therapy in Patients with Residual Disease
Clinicians should regularly evaluate recent clinical trial data to make informed decisions on the most appropriate treatment plan, particularly as new targeted therapies, as well as new indications for existing targeted therapies, become FDA-approved.
Category
- Gastric/Esophageal Cancer
Format
- Live Webinar
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 CCM clock hours
- 1.00 Participation
Recorded Presentation from the NCCN Pharmacy Updates: Updates in Biomarker-Driven Therapy in Non-Small Cell Lung Cancer
The biomarker-driven treatment of non-small cell lung cancer is evolving rapidly and pharmacists should be aware of new data, therapies, and treatment recommendations in order to support the multidisciplinary health care team and provide optimal patient care.
Category
- Lung Cancers
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation
Implementation of a Hematology Outpatient Sepsis Alert Protocol
Quality initiatives directed at standardized clinical pathways for symptom management, and development for urgent cancer care tactics are becoming a standard in cancer care to help reduce sepsis and the need for acute care.
Category
- Supportive Care Topics
Format
- Recorded Webcast
Credits
- 0.75 ANCC contact hours
- 0.75 Participation
Palliative Care and Hematologic Malignancies: Can They Co-Exist?
Education on the use of palliative care resources is important to help hematology oncology clinicians potentially lessen the bias that may surround including “outsiders” in the care of their patients, thus allowing these patients and their caregivers to experience the benefits of this resource earlier in their care.
Category
- Palliative Care
- Supportive Care Topics
Format
- Recorded Webcast
Credits
- 0.75 ANCC contact hours
- 0.75 Participation
Key Assessment and Evaluation Strategies After CAR T-Cell Therapy
The management of adverse effects, including toxicity from treatment as well as the education of patients and the coverage of these treatments by insurance are imperative to good clinical care of patients receiving these therapies.
Category
- Supportive Care Topics
Format
- Recorded Webcast
Credits
- 0.75 ANCC contact hours
- 0.75 Participation
Updates in the Management of Graft-Versus-Host Disease
Educating nurses in the identification of symptoms and the treatments available will increase the identification and early treatment of GVHD in patients. Nurses are in a perfect position to include other team members to address the psychosocial and palliative/symptomatic care of patients with GVHD, both acute and chronic.
Category
- Supportive Care Topics
Format
- Recorded Webcast
Credits
- 0.75 ANCC contact hours
- 0.75 Participation
Patient Case Studies and Panel Discussion: Management of Acute Lymphoblastic Leukemia
It is critically important for oncology care providers to be aware of the best ways to incorporate these advances into standard practice so that each patient can receive optimal care.
Category
- Acute Lymphoblastic Leukemia
Format
- Recorded Webcast
Credits
- 1.25 AAPA Category 1 CME credit
- 1.25 ACPE contact hours
- 1.25 AMA PRA Category 1 Credit™
- 1.25 ANCC contact hours
- 1.25 Participation
New Treatment Options and Toxicity Management in Acute Lymphoblastic Leukemia
Newer agents used in the treatment of acute lymphoblastic leukemia (ALL) have led to improved clinical outcomes, but are associated with significant toxicities. Clinicians need to be educated on appropriate management approaches for the side effects associated with these new therapies to allow patients to receive maximal benefit and optimal care.
Category
- Acute Lymphoblastic Leukemia
Format
- Recorded Webcast
Credits
- 1.00 AAPA Category 1 CME credit
- 1.00 ACPE contact hours
- 1.00 AMA PRA Category 1 Credit™
- 1.00 ANCC contact hours
- 1.00 Participation